Phase II trial of pirfenidone in adults with neurofibromatosis type 1

Dusica Babovic-Vuksanovic, K. Ballman, V. Michels, P. McGrann, Noralane Morey Lindor, Bernard Francis King, J. Camp, V. Micic, N. Babovic, X. Carrero, R. Spinner, Brian Patrick O'Neill

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

We performed an open-label phase II trial of oral pirfenidone in 24 patients with neurofibromatosis type 1 (NF1). Tumors were monitored by three-dimensional MRI. At the end of treatment, four patients had a decrease in tumor volume by 15% or more, three had tumor progression, and 17 remained stable. Pirfenidone warrants further investigation in NF1, which has until now lacked an effective control therapy.

Original languageEnglish (US)
Pages (from-to)1860-1862
Number of pages3
JournalNeurology
Volume67
Issue number10
DOIs
StatePublished - Nov 2006

Fingerprint

Neurofibromatosis 1
Tumor Burden
Neoplasms
Therapeutics
pirfenidone

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Phase II trial of pirfenidone in adults with neurofibromatosis type 1. / Babovic-Vuksanovic, Dusica; Ballman, K.; Michels, V.; McGrann, P.; Lindor, Noralane Morey; King, Bernard Francis; Camp, J.; Micic, V.; Babovic, N.; Carrero, X.; Spinner, R.; O'Neill, Brian Patrick.

In: Neurology, Vol. 67, No. 10, 11.2006, p. 1860-1862.

Research output: Contribution to journalArticle

Babovic-Vuksanovic, D, Ballman, K, Michels, V, McGrann, P, Lindor, NM, King, BF, Camp, J, Micic, V, Babovic, N, Carrero, X, Spinner, R & O'Neill, BP 2006, 'Phase II trial of pirfenidone in adults with neurofibromatosis type 1', Neurology, vol. 67, no. 10, pp. 1860-1862. https://doi.org/10.1212/01.wnl.0000243231.12248.67
Babovic-Vuksanovic, Dusica ; Ballman, K. ; Michels, V. ; McGrann, P. ; Lindor, Noralane Morey ; King, Bernard Francis ; Camp, J. ; Micic, V. ; Babovic, N. ; Carrero, X. ; Spinner, R. ; O'Neill, Brian Patrick. / Phase II trial of pirfenidone in adults with neurofibromatosis type 1. In: Neurology. 2006 ; Vol. 67, No. 10. pp. 1860-1862.
@article{200a8857bee94a1ea36acd0891f29414,
title = "Phase II trial of pirfenidone in adults with neurofibromatosis type 1",
abstract = "We performed an open-label phase II trial of oral pirfenidone in 24 patients with neurofibromatosis type 1 (NF1). Tumors were monitored by three-dimensional MRI. At the end of treatment, four patients had a decrease in tumor volume by 15{\%} or more, three had tumor progression, and 17 remained stable. Pirfenidone warrants further investigation in NF1, which has until now lacked an effective control therapy.",
author = "Dusica Babovic-Vuksanovic and K. Ballman and V. Michels and P. McGrann and Lindor, {Noralane Morey} and King, {Bernard Francis} and J. Camp and V. Micic and N. Babovic and X. Carrero and R. Spinner and O'Neill, {Brian Patrick}",
year = "2006",
month = "11",
doi = "10.1212/01.wnl.0000243231.12248.67",
language = "English (US)",
volume = "67",
pages = "1860--1862",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Phase II trial of pirfenidone in adults with neurofibromatosis type 1

AU - Babovic-Vuksanovic, Dusica

AU - Ballman, K.

AU - Michels, V.

AU - McGrann, P.

AU - Lindor, Noralane Morey

AU - King, Bernard Francis

AU - Camp, J.

AU - Micic, V.

AU - Babovic, N.

AU - Carrero, X.

AU - Spinner, R.

AU - O'Neill, Brian Patrick

PY - 2006/11

Y1 - 2006/11

N2 - We performed an open-label phase II trial of oral pirfenidone in 24 patients with neurofibromatosis type 1 (NF1). Tumors were monitored by three-dimensional MRI. At the end of treatment, four patients had a decrease in tumor volume by 15% or more, three had tumor progression, and 17 remained stable. Pirfenidone warrants further investigation in NF1, which has until now lacked an effective control therapy.

AB - We performed an open-label phase II trial of oral pirfenidone in 24 patients with neurofibromatosis type 1 (NF1). Tumors were monitored by three-dimensional MRI. At the end of treatment, four patients had a decrease in tumor volume by 15% or more, three had tumor progression, and 17 remained stable. Pirfenidone warrants further investigation in NF1, which has until now lacked an effective control therapy.

UR - http://www.scopus.com/inward/record.url?scp=33845413549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845413549&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000243231.12248.67

DO - 10.1212/01.wnl.0000243231.12248.67

M3 - Article

C2 - 17035676

AN - SCOPUS:33845413549

VL - 67

SP - 1860

EP - 1862

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 10

ER -